Saliva

Unlocking Menopause's Hidden Impact: 84% of Women 50 and Older Unaware of Menopause-Oral Health Connection

Retrieved on: 
Monday, September 18, 2023
Learning, Education, Xerostomia, Menopause, Overalls, Policy, Woman, Dental hygienist, Pain, Dentist, Delta Dental, Tooth decay, Patient, Chavarria, SAN, Knowledge, Ageing, Health, Mouth, Saliva, Dentistry, Birth control

SAN FRANCISCO, Sept. 18, 2023 /PRNewswire/ -- An astounding 84% of women aged 50 and over are unaware that some of the oral health symptoms and discomfort they experience could be related to menopause, according to Delta Dental's 2023 Senior Oral Health and Menopause Report: Breaking the Stigma.

Key Points: 
  • Delta Dental's first Senior Oral Health and Menopause Survey revealed that 70% of women 50 and older experience oral health symptoms they don't realize relate to menopause, making dentists a prime, untapped resource for women navigating it.
  • Though 70% of women 50 and older indicated they have experienced at least one oral health symptom since beginning menopausal symptoms, only 2% have discussed their concerns with their dentist and only 1% with their dental hygienist.
  • "Despite the knowledge gaps revealed in this survey, sentiments about menopause are beginning to shift, and women are eager to break the stigma.
  • More than 2 in 5 women 50 and older (43%) say they will spend much more time on their oral health care routine.

Global Drug of Abuse Testing Market Analysis Report 2023-2030: Regulatory Status, Recent Developments, Company Profiles, Drivers and Challenges - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Pharmaceutical, Health, Medical Devices, Hair, Urine, Workplace, Abuse, Fatality, UNODC, Delaware Division of Alcohol and Tobacco Enforcement, US, Public health, Traction, Blood, UN, United Kingdom, Growth, Diagnosis, Ageing, Saliva, Disease, Addiction, Pharmaceutical industry, Drug, Medical device, Crime, Perspiration

The "Global Drug of Abuse Testing Market (By Product Type, Sample/Test Type, Drug Type, End Users/Setting Type, Region), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug of Abuse Testing Market (By Product Type, Sample/Test Type, Drug Type, End Users/Setting Type, Region), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Driving the drug of abuse testing market is the stringent regulatory framework against illicit drug consumption, intensified due to the growing instances of global drug abuse.
  • An innovative trend gaining traction is fingerprint-based drug testing, offering a promising avenue for major industry players in the global drug screening market.
  • North America dominates the global drug of abuse testing market and is expected to lead the market over the forecast period.

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, MSD, Vaccination, Chills, Public, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Ebola, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, EC, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

Key Points: 
  • The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
  • “Ebola virus disease is severe and potentially life-threatening for both children and adults.
  • INDICATIONS AND USAGE IN THE U.S.
    ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

Is it okay to kiss your pet? The risk of animal-borne diseases is small, but real

Retrieved on: 
Monday, September 4, 2023
Salmonellosis, Infection, Human, Food, Rabies virus, Bird, Disease, Toxoplasma gondii, Parasitism, Prevalence, Bartonella henselae, Face, Aerosol, Turtle, Campylobacteriosis, Dog, Toxoplasmosis, MRSA, Biting, Fungus, Hygiene, Cat, Thought, Mycobacterium, Giardiasis, Animal, Soil, Population, Psittacosis, Risk, Water, Pet, Rabies, Bacteria, Genetically modified bacteria, Birth, Death, Scratch, Virus, Meningitis, Pneumonia, Mouth, Saliva, Pet industry, Medical imaging, Vaccine, Trapping, Veterinary medicine, Animal husbandry, Pig, Poultry farming, Toy, Zoonosis

Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.

Key Points: 
  • Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.
  • We spend an estimated A$33 billion every year on caring for our fur babies.
  • But some, such as pregnant people and those with weakened immune systems, are at greater risk of getting sick from animals.

What diseases can pets carry?

    • Infectious diseases that move from animals to humans are called zoonotic diseases or zoonoses.
    • Zoonoses can be transmitted directly from pets to humans, such as through contact with saliva, bodily fluids and faeces, or indirectly, such as through contact with contaminated bedding, soil, food or water.
    • Both dogs and cats are also reservoirs for methicillin-resistant bacterium Staphylococcus aureus (MRSA), with close contact with pets identified as an important risk factor for zoonotic transmission.
    • Read more:
      Cats carry diseases that can be deadly to humans, and it's costing Australia $6 billion every year

Birds, turtles and fish can also transmit disease

    • Pet birds can occasionally transmit psittacosis, a bacterial infection which causes pneumonia.
    • Contact with pet turtles has been linked to Salmonella infections in humans, particularly in young children.
    • Even pet fish have been linked to a range of bacterial infections in humans, including vibriosis, mycobacteriosis and salmonellosis.
    • Close contact with animals – and some behaviours in particular – increase the risk of zoonotic transmission.

What should I do if I’m worried about catching a disease from my pet?


    There are a number of good hygiene and pet husbandry practices that can reduce your risk of becoming sick. These include:
    It is especially important for those who are at a higher risk of illness to take precautions to reduce their exposure to zoonotic pathogens. And if you’re thinking about getting a pet, ask your vet which type of animal would best suit your personal circumstances.

    Read more:
    One in three people are infected with _Toxoplasma_ parasite – and the clue could be in our eyes

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
Thursday, August 31, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Pancreatic cancer, 23andMe, PCCP, DNA, Disease, Sanger, Ashkenazi Jews, Genetics, BRCA1, Food and Drug Administration, Cancer, Breast, Prostate, PGS, Marketing, Risk, Artificiality, Genetic testing, Entrepreneurship, BRCA2, BRCA, Health, FDA, Ovarian cancer, Gene, African Americans, Food, Saliva, Breast cancer, Prostate cancer, Birth control, Medical device, Pharmaceutical industry, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights

Retrieved on: 
Thursday, August 24, 2023
Haulage, University, Diabetes, Quarter, Eastern Airways, Classification, Marketing, Cortisol, Government, U.S. FDA, TTR, Correlation, Blood, The Company, Acquisition, Patent, Collection, Growth, FDA, Intelligence, Supplement, Saliva, Medical device, Pharmaceutical industry, Cryptocurrency, Airline, Glucose

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update.

Key Points: 
  • “In the 2023 fiscal year, we maintained rapid expansion of our customer footprint, successfully entering the Australian market with accelerated uptake,” said Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions.
  • In addition, we further strengthened the protection of our unique and proprietary drug screening technology with the award of our 13th patent.
  • The results showed a record 4x improvement in TTR, enabling the biosensor to return test results in under one minute.
  • Fourth Quarter and Full Year Ended June 30, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Multimedia, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Retrieved on: 
Tuesday, August 22, 2023
Research, Other Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, Other Science, Pressure, DNA, Fisher Scientific, Centre for Applied Genomics, Thermo Fisher Scientific, Chas, Amniotic fluid, Data analysis, Genome, AIR, Blood, GCS, Saliva, Management, Medical imaging

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.
  • “Thermo Fisher Scientific is committed to innovation to meet the needs of our customers,” said Kevin Lowitz, vice president and general manager, microarray genetic solutions, Thermo Fisher Scientific.
  • As part of its commitment to enabling customers to advance cytogenetic research, Thermo Fisher has continued to update its instrumentation and services.
  • Thermo Fisher has also upgraded its high-performance microarray instrument for array processing, Applied Biosystems™ GeneChip™ System (GCS) 3000 , with the autoloader pre-assembled inside the scanner for more efficient installation and a modernized look.

What's in vapes? Toxins, heavy metals, maybe radioactive polonium

Retrieved on: 
Thursday, August 10, 2023
People, Carcinogen, Nicotine, Urinary tract infection, Aerosol, Atmosphere, Urine, Marketing, Organic compound, Propylene glycol, Cancer, Eating, Lead, Research, Plant, Soil, Chromium, Laboratory, Nickel, Polonium, Blood, Particulates, Arsenic, Acetaldehyde, Heat, Heated tobacco product, Smoking, News, Tobacco smoking, Saliva, Herbal cigarette, Tobacco, Environmental remediation, Natural gas, Dietary supplement, Maple syrup

If you asked me what’s in e-cigarettes, disposable vapes or e-liquids, my short answer would be “we don’t fully know”.

Key Points: 
  • If you asked me what’s in e-cigarettes, disposable vapes or e-liquids, my short answer would be “we don’t fully know”.
  • E-cigarettes’ risk to health varies depending on many factors including which device or flavours are used, and how people use them.
  • So vapers just don’t know what they’re inhaling and cannot be certain of the health impacts.

What do we know?

    • Ingredients include nicotine, flavouring chemicals, and the liquids that carry them – primarily propylene glycol and glycerine.
    • Concerningly, we also find volatile organic compounds, particulate matter and carcinogens (agents that can cause cancer), many of which we know are harmful.
    • Our previous research also found 2-chlorophenol in about half of e-liquids users buy to top-up re-fillable e-cigarettes.

How about polonium?

    • That’s because tobacco plants absorb it and other radioactive materials from the soil, air and high-phosphate fertiliser.
    • Although it is feasible if the glycerine in e-liquids comes from plants and similar fertilisers are used to grow them.

It’s not just the ingredients

    • Aside from their ingredients, the materials e-cigarette devices are made from can end up in our bodies.
    • Toxic metals and related substances such as arsenic, lead, chromium and nickel can be detected in both e-liquids and vapers’ urine, saliva and blood.

That’s not all


    The process of heating e-liquids to create an inhalable aerosol also changes their chemical make-up to produce degradation products. These include:
    • However due to different devices and how the samples are collected, the levels measured vary widely between studies.
    • Often, the levels are very low, leading to proponents of vaping arguing e-cigarettes are far safer than tobacco smoking.
    • People who buy tobacco cigarettes are also confronted with a plethora of warnings about the hazards of smoking, while vapers generally are not.

How about labelling?

    • Even if labels are present, they don’t always reflect what’s in the product.
    • Nicotine concentration of e-liquids is often quite different to what is on the label, and “nicotine-free” e-liquids often contain nicotine.
    • However mixing them into e-liquids, heating and inhaling them is a very different type of exposure, compared to eating them.
    • The list is so short because we don’t have enough information on the health effects if inhaled of other flavouring chemicals, and their interactions with other e-liquid ingredients.

Where to next?


    For us to better assess the health risks of vapes, we need to learn more about:
    Finally, we need to know more about how people use e-cigarettes so we can better understand and quantify the health risks in the real world.